-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

704.O1.6 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: CAR-T Cell Therapies for Lymphomas and ALL: New Strategies and Toxicities

Symposia: Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Lymphoid Leukemias, ALL, Adult, Lymphomas, Non-Hodgkin lymphoma, Translational Research, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Health outcomes research, Diseases, Indolent lymphoma, Treatment Considerations, Biological therapies, Aggressive lymphoma, Immunotherapy, Real-world evidence, Lymphoid Malignancies, Adverse Events, Infusion, Technology and Procedures, Natural Killer (NK) Cell Therapies, Study Population, Human, Measurable Residual Disease
Saturday, December 7, 2024: 9:30 AM-11:00 AM
Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)
Moderators:
Chenyu Lin, MD, Duke University School of Medicine and Kathryn Cappell, National Cancer Institute
Disclosures:
Lin: Autolus: Consultancy; Rigel: Consultancy; ADC Therapeutics: Consultancy.
9:30 AM

Mingming Zhang1*, Yongxian Hu1*, Guoqing Wei1*, Shan Fu1*, Jingjing Feng1*, Ruimin Hong1*, Alex H. Chang, Ph.D2,3* and He Huang4*

1Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2Shanghai YaKe Biotechnology Ltd., Shanghai, China
3Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China, Shanghai, China
4Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

9:45 AM

Yugang Guo, PhD1,2,3*, Qianwen Xu, Master1*, Lei Xue, Master1*, Erlin Chen, Master1*, Xuhan Zhang, MD1*, Chonglin Liu, Master2*, Min Gao, PhD2,3*, Youjia Li, PhD2*, Jingjing Ren, PhD, MD2*, Karthik Sathiyanadan, PhD2*, Li Tang, PhD4,5*, He Huang, MD6,7,8,9,10*, Yongxian Hu7,9,11,12* and Xingbing Wang13*

1Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
2Leman Biotech Co., Ltd., Shenzhen, China
3Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University; State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China
4Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
5Institute of Materials Science & Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
6Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
7The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8Bone marrow transplantation department, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
9Institute of Hematology, Zhejiang University, Hangzhou, China
10Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
11Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China
12Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
13Department of Hematology, The First Affiliated Hospital of USCT (Anhui Provincial Hospital), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

10:00 AM

Marie José Kersten, MD, PhD1*, Kirsten Saevels2, Evelyne Willems3*, Marte C. Liefaard4*, Stavros Milatos5*, Margot J. Pont4*, Claire Vennin4*, Eva Santermans6*, Anna D. D. van Muyden4, Jeevan Shetty, MD7, Esmée P. Hoefsmit4*, Omotayo Fasan8*, Maria T. Kuipers9*, Sébastien Anguille, MD2* and Joost S.P. Vermaat10

1Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
2Antwerp University Hospital, Antwerp, Belgium
3Centre Hospitalier Universitaire de Liège, Liège, Belgium
4Galapagos BV, Oegstgeest, Netherlands
5Galapagos GmbH, Basel, Switzerland
6Galapagos NV, Mechelen, Belgium
7Galapagos, Mechelen, Belgium
8Galapagos Inc., Princeton, NJ
9Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands
10Department of Hematology, Leiden University Medical Center, Leiden, Netherlands

10:15 AM

Changchun Deng, MD1*, Paolo F. Caimi2, Umar Farooq, MD3, Nethrie Idippily, PhD4*, Maria Florencia Giraudo4*, Jane S. Reese5*, Sarah Kleinsorge-Block1*, Daniel Caley5*, Ryan Stadel, PhD4*, Koen van Besien, MD, PhD6, Marcos de Lima7*, Arun Kumar Arunachalam, MD8*, J. Joseph Melenhorst, PhD9 and David Wald, MD PhD4,5*

1University Hospitals Cleveland Medical Center, Cleveland, OH
2Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
4Kure.ai, Cleveland, OH
5Case Western Reserve University, Cleveland, OH
6Department of Hematology and Stem Cell Transplant, University Hospitals Seidman Cancer Center, Cleveland, OH
7Division of Hematology, The Ohio State University, Columbus, OH
8Cleveland Clinic Foundation, Cleveland
9Center for Immunotherapy and Precision Immuno-Oncology, Cell Therapy & Immuno-Engineering Program, Lerner Research Institute, Cleveland Clinic, Cleveland, OH

10:30 AM

Justin M. Darrah, MD1*, Indumathy Varadarajan2*, Amitkumar Mehta, MD3*, Jennifer N. Saultz, DO4, Matthew McKinney, MD5*, Monalisa Ghosh, MD6, Usama Gergis, MD, MBA7, Girish Bende8*, Siddha Kasar, PhD8*, Bradley Hupf8*, Sharon Chen8*, Leopold Sellner8* and Reem Karmali, MD9

1Division of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
2University of Virginia, Charlottesville, VA
3University of Alabama at Birmingham, Birmingham, AL
4Knight Cancer Institute, Oregon Health & Science University, Portland, OR
5Duke Cancer Institute, Durham, NC
6University of Michigan, Ann Arbor, MI
7Thomas Jefferson University, Philadelphia, PA
8Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
9Northwestern Memorial Hospital, Chicago, IL

10:45 AM

Mark Hamilton, MD1, Nick Phillips2*, Dasom Lee, MD3, Zachary Ehlinger, MS4*, Anne Marijn Kramer, MD, PhD5, Hrishikesh Srinagesh6*, Zinaida Good, PhD4, Xiaoman Kang, BS7*, Mari Olsen, BS8*, Chih Long Liu, PhD8*, Feng Tian, PhD8*, Brian J. Sworder, MD, PhD9, Hitomi Hosoya, MD, PhD10, Joseph G. Schroers-Martin, MD11, Sushma Bharadwaj, MD12, Sally Arai, MD10, Laura Johnston, MD10, Robert Lowsky, MD13*, Everett H. Meyer, MD, PhD13, Robert S. Negrin, MD10, Andrew R. Rezvani10*, Judith Shizuru10*, Lekha Mikkilineni, MD, MA14, Parveen Shiraz10*, Surbhi Sidana, MD13, Wen-Kai Weng, MD, PhD12, Vanessa E. Kennedy, MD12, Melody Smith, MD, MS13, Lori Muffly, MD13, David Kurtz, MD, PhD15, Saurabh Dahiya, MD, FACP10*, Matthew J. Frank, MD, PhD12, Crystal L. Mackall, MD4, Bita Sahaf10*, David B. Miklos, MD, PhD16 and Ash A. Alizadeh, MD, PhD17,18

1Stanford Cancer Institute, Center for Cancer Cell Therapy, Stanford University, Stanford, CA
2Stanford Cancer Institute, Stanford University Medical School, Palo Alto, CA
3Department of Medicine, Division of Oncology, Stanford University, Redwood City, CA
4Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
5Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Menlo Park, CA
6Stanford University, Stanford
7Department of Medicine, Division of Oncology, Stanford University, Stanford, CA
8Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA
9Division of Oncology, Department of Medicine, Stanford University, Stanford, CA
10Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
11Department of Medicine, Division of Oncology and Hematology, Stanford University, Menlo Park, CA
12Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
13Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA
14Stanford University, Stanford, CA
15Department of Medicine (Oncology), Stanford University, Palo Alto, CA
16Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Palo Alto, CA
17Stanford Cancer Institute, Institute for Stem Cell Biology & Regenerative Medicine, Stanford, CA
18Stanford University, San Mateo, CA

*signifies non-member of ASH